Rockwell Medical and Innovative Renal Care Ink Three-Year Deal to Ensure Hemodialysis Product Supply Chain Continuity
Reuters
Jul 08
Rockwell Medical and Innovative Renal Care Ink Three-Year Deal to Ensure Hemodialysis Product Supply Chain Continuity
Rockwell Medical, Inc., a healthcare company specializing in hemodialysis products, has entered a three-year partnership agreement with Innovative Renal Care (IRC), one of the largest dialysis service providers in the U.S. The agreement ensures the reliable supply of high-quality hemodialysis concentrates to IRC's clinics, focusing on streamlining workflows and preventing supply chain disruptions. Rockwell Medical will provide IRC with both liquid and dry acid and bicarbonate concentrates, including the DAMX45 dry acid concentrate mix system, enhancing storage efficiency and product continuity. The multi-million dollar agreement includes utilization commitments and an option to extend for an additional year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rockwell Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250708397524) on July 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.